Follicles (bridge sign), a fragment of the hair shaft extruding through a dilated hair follicle (sword sign) and retained cylindrical fragments of keratin in the dermis.7

Eventually, the ultrasound allows to improve the surgical approach, allowing more targeted interventions both in relation to the moment in which to perform the surgery and in establishing the extension of the surgical approach.

C. Marasca, D. Marasca, M. Megna, M.C. Annunziata, G. Fabbrocini

1Department of Clinical Medicine and Surgery, Section of Dermatology, University of Naples Federico II, Napoli, Italy, 2Department of Dentistry, University of Naples Federico II, Napoli, Italy

*Correspondence: C. Marasca. E-mail: claudio.marasca@gmail.com

Linked article: L. Fertitta et al. J Eur Acad Dermatol Venereol 2020;34:e412—e413. https://doi.org/10.1111/jdv.16359.

References

1 Fertitta L, Hotz C, Wolkenstein P et al. Efficacy and satisfaction of surgical treatment for hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020;34:839–845.
2 Wortsman X, Moreno C, Soto R, Arellano J, Pezo C, Wortsman J. Ultrasound in-depth characterization and staging of hidradenitis suppurativa. Dermatol Surg 2013;39:1833–1842.
3 Wortsman X, Jemec GBE. Real-time compound imaging ultrasound of hidradenitis suppurativa. Dermatol Surg 2007;33:1340–1342.
4 Lacarrubba F, Dini V, Napolitano M et al. Ultrasonography in the pathway to an optimal standard of care of hidradenitis suppurativa: the Italian Ultrasound Working Group experience. J Eur Acad Dermatol Venereol 2019;33(Suppl 6):10–14.
5 Martorell A, Allageme Roldán F, Vilarrasa RE. Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. J Eur Acad Dermatol Venereol 2019;33:2137–2142.
6 Martorell A, Giovanardi G, Gomez-Palencia P, Sanz-Motilva V. Defining fistular patterns in hidradenitis suppurativa: impact on the management. Dermatol Surg 2019;45:1237–1244.
7 Wortsman X, Calderon P, Castro A. seventy-MHz ultrasound detection of early signs linked to the severity, patterns of keratin fragmentation, and mechanisms of generation of collections and tunnels in hidradenitis suppurativa. J Ultrasound Med 2019. https://doi.org/10.1002/jum.15164. [Epub ahead of print];

DOI: 10.1111/jdv.16361

Table 1 Clinical characteristics of the 81 patients with skin and soft-tissue infections (SSTIs) caused by Aeromonas species, French Guiana, 2007–2018

| Characteristics                      | No. (%) of patients. n = 81 |
|--------------------------------------|-----------------------------|
| Age (years)                          | 40 (79)                     |
| Male gender                          | 64 (79)                     |
| Female gender                        | 17 (21)                     |
| Geographic origin                    |                             |
| Cayenne metropolitan area            | 44 (54)                     |
| Upper Maroni                         | 25 (31)                     |
| Coastal region                       | 8 (10)                      |
| Other                                | 4 (5)                       |
| Underlying condition                 |                             |
| Diabetes mellitus                    | 10 (12)                     |
| Organ failure                        | 7 (9)                       |
| Wound location                       |                             |
| Lower limb                           | 58 (72)                     |
| Upper limb                           | 12 (15)                     |
| Chest                                | 5 (6)                       |
| Head                                 | 5 (6)                       |
| Abdomen                              | 1 (1)                       |
| Exposure                             |                             |
| Road trauma                          | 22 (27)                     |
| Snake bite                           | 16 (20)                     |
| Chronic wound                        | 9 (11)                      |
| Water exposure                       | 8 (10)                      |
| Burn                                 | 7 (9)                       |
| Metallic foreign object              | 7 (9)                       |
| Firearm                              | 6 (7)                       |
| Stingray stabbing                    | 3 (4)                       |
| Unknown                              | 3 (4)                       |
| Wood foreign object                  | 2 (2)                       |
| Dog bite                             | 1 (1)                       |
| Clinical presentation                |                             |
| Localized wound infection            | 36 (44)                     |
| Necrotizing fasciitis                | 17 (21)                     |
| Abscess                              | 15 (19)                     |
| Cellulitis                           | 8 (10)                      |
| Infected ulcer                       | 5 (6)                       |
| Organism                             |                             |
| A. hydrophila                        | 76 (94)                     |
| A. caviae                            | 4 (5)                       |
| A. jandaei                           | 1 (1)                       |
| Type of infection                    |                             |
| Polymicrobial infection              | 63 (79)                     |
| Monomicrobial infection              | 18 (21)                     |
| Management                           |                             |
| Antibiotic therapy only              | 42 (52)                     |
| Wound debridement                    | 28 (35)                     |
| Amputation                           | 11 (14)                     |
| Issue                                |                             |
| Complete healing                     | 60 (74)                     |
| Amputation                           | 11 (14)                     |
| Evacuation to mainland France        | 6 (7)                       |
| Death                                | 2 (3)                       |
| Chronic evolution                    | 2 (3)                       |

Skin and soft-tissue infections associated with Aeromonas species in French Guiana: an 11-year retrospective study

Editor

Aeromonas species are Gram-negative bacilli, commonly found in salted and fresh water, food and soil.1 Skin and soft-tissue infections (SSTIs) are frequent2 and have been reported in Australia,1 Asia3 and the Indian Ocean.4 However, data from South America are scarce. We investigated the exposures, clinical characteristics and antimicrobial susceptibilities of Aeromonads

JEADV 2020, 34, e346–e432 © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
involved in SSTIs in French Guiana. We looked for risk factors of unfavourable outcome.

We retrospectively included all patients with skin or soft-tissue infections and a positive culture with Aeromonas spp, seen in the Cayenne Hospital between 2007 and 2018.

A total of 81 patients were included. Clinical and epidemiological data are gathered in Table 1. Numbers of infections for each month of the year are presented in Fig. 1. The more frequent exposures were road trauma (n=22) and snake bites (n=16). Clinical presentations were often severe, including necrotizing fasciitis (n=17) and abscesses (n=15). Eleven patients required amputation.

Antibiotic resistance profile was known for 77 patients (95%). Most strains were resistant to ticarcillin (72%). Less than 5% were resistant to ciprofloxacin, imipenem or gentamicin. None were resistant to cefazidime or amikacin.

Aeromonas hydrophila was the most common pathogen (n=76, 94%). The majority of patients had polymicrobial infections, mostly with enterobacteriae (n=27, 33%) and Staphylococcus aureus (n=15, 19%). One half of monomicrobial infections (n=18, 22%) were caused by snake bites.

Concerning the outcome, two patients died, including a 61-year-old woman with A. hydrophila bacteraemia and a 71-year-old diabetic woman with a necrotizing fasciitis growing A. hydrophila and Klebsiella pneumonia. They both received amoxicillin–clavulanate though both germs were resistant. Antibiotics covering Aeromonas and frequent co-pathogens should then be contemplated (third-generation cephalosporin or fluoroquinolone).2 Patients with burns in rainforest areas should be closely monitored due to the high risk of unfavourable outcome.

Concerning clinical features, the proportion of necrotizing fasciitis (n=17, 21%) was higher than in most previous studies,6 excepting a report of Aeromonads infections after a tsunami in Thailand.3 This frequent severity could be explained by a delay in treatment due to a lack of healthcare access in remote areas of French Guiana. Though previous studies reported an important proportion of immunocompromised patients,2,5 such a feature was not observed in our cohort. Thus, Aeromonads infections should also be expected in healthy young men performing at-risk outdoor activities.

In multivariate analysis, burns were associated with unfavourable issue, mirroring previous case reports of high mortality in burned patients infected with Aeromonads.10 The only two deaths occurred when antibiotics were not adapted to antibiograms. These results highlight the importance of antibiotic stewardship in circumstances of burns, waterborne or telluric contaminations. Antibiotics covering Aeromonas and frequent co-pathogens should then be contemplated (third-generation cephalosporin or fluoroquinolone).2 Patients with burns in rainforest areas should be closely monitored due to the high risk of unfavourable outcome.

M. Devos,1 V. Sainte-Rose,2 H. Kallel,3 C. Mayence,3 H. Ouedraogo,4 F. Djossou,5,6 M. Demar2,6 P. Couppié,1,6 R. Blaizot1,6,*

1Dermatology Department, Hôpital André Rosemon, Cayenne, French Guiana; 2Laboratory of Bacteriology, Hôpital André Rosemon, Cayenne, French Guiana; 3Intensive Care Unit, Hôpital André Rosemon, Cayenne, French Guiana; 4Orthopaedics Department, Hôpital André Rosemon, Cayenne, French Guiana; 5Infectious Diseases Department, Hôpital André Rosemon, Cayenne, French Guiana; 6EA 3593, Ecosystèmes Amazoniens et Pathologies Tropicales, University of French Guiana, Cayenne, French Guiana

*Correspondence: R. Blaizot. E-mail: Blaizot.romain@gmail.com

References

1. McAluifte GN, Hennessy J, Baird RW. Relative frequency, characteristics, and antimicrobial susceptibility patterns of Vibrio spp., Aeromonas spp., Chromobacterium violaceum, and Shewanella spp. in the northern territory of Australia, 2000–2013. Am J Trop Med Hyg 2015; 92: 605–610.
Comparative 12-week effectiveness and safety outcomes of biologic agents ustekinumab, secukinumab and ixekizumab for the treatment of plaque psoriasis: a real-world multicenter retrospective study

Editor

Today, dermatologists commonly prescribe ustekinumab, secukinumab and ixekizumab in routine clinical practice due to their proven success rate. At this time, real-life comparison between these three treatments is scarce. Our aim was to compare head-to-head the clinical effectiveness and associated reported adverse events (AEs) of ustekinumab, secukinumab and ixekizumab within routine clinical practice.

Following research ethics approval, a multicenter retrospective chart review was undertaken of patients from two tertiary academic hospitals in Toronto, Canada seen in clinic between January 2014 and January 2018. Inclusion criteria were consecutive patients 18 years of age or older with moderate-to-severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 10) and treated with either ustekinumab, secukinumab or ixekizumab. Patients receiving concomitant systemic treatment (phototherapy, methotrexate, soriatane or cyclosporine) were screened to ensure that the concomitant therapy had been used for at least 12 weeks before initiation of the biologic treatment and patients were maintained on a stable dose throughout the 12-week study period to mitigate confounding efficacy and safety outcomes. Treatment failure included those who discontinued treatment due to lack of efficacy, intolerance or other non-drug-related reasons. The clinically significant efficacy endpoints were PASI 75 and PASI 100 following 12 weeks of biologic treatment. Achievement of physician global assessment (PGA) of 0 (clear) or 1 (almost clear) was used for a select group of patients without documented PASI scores at 12 weeks. Safety endpoints were quantified by patient- or clinician-reported AEs.

A total of 180 patients met inclusion criteria, of which 60 were treated with ustekinumab, 60 with secukinumab and 60 with ixekizumab; according to product monograph (Table 1). Significantly different baseline characteristics included lower mean number of co-morbidities in the ustekinumab (0.8 ± 1.0) treatment group compared with secukinumab (1.6 ± 1.4) and ixekizumab (1.7 ± 1.4) (P = 0.001). The ustekinumab cohort had significantly fewer previously failed systemic and biologic therapies (2.6 ± 1.3; 0.8 ± 0.9) compared with secukinumab (4.8 ± 1.9; 2.4 ± 1.2) and ixekizumab (4.6 ± 2.1; 2.6 ± 1.6) (P < 0.001). Of those in the ustekinumab group, 51.7% had previously failed a biologic therapy, compared with 98.3% for secukinumab and 93.3% for ixekizumab (P < 0.001). All significantly different baseline characteristics were included in the statistical analysis to correct for their possible confounding effect.

Efficacy. No significant differences in clinical efficacy primary endpoints were observed at week 12 (P > 0.05) (Table 1). PASI 75 response rates were comparable between ustekinumab (73.3%), secukinumab (76.7%), and ixekizumab (75.0%) treated patients (P = 0.851, P = 0.389, P = 0.574, respectively). PASI 100 rates at week 12 were comparable for all three cohorts, with ustekinumab (30.0%) and secukinumab (25.0%) showing lower rates than ixekizumab (35.0%). Similarly, phase 3 randomized controlled trials (RCT) showed that 66.4-75.7%/10.9-18.2%, 75.9-81.6%/24.1-43.1% and 87.3-89.7%/35.3-40.5% of patients treated with ustekinumab, secukinumab and ixekizumab achieved PASI 75/100, respectively.1,2,3,4 Logistic regression looking at the possible effect of prior failed systemic and biologic use, baseline PASI and presence of co-morbidities on efficacy showed that these factors did not significantly impact PASI 75 outcomes (P > 0.05 for all variables assessed). None of these factors had a significant effect on PASI 100 outcomes (P > 0.05 for all variables assessed).

Safety. Ixekizumab was associated with a significantly higher incidence of AEs (P = 0.001) compared with ustekinumab and secukinumab (Table 1). AEs were reported by 12 (17.4%) and 22 (36.7%) patients in the ustekinumab, secukinumab and ixekizumab groups, respectively. Rates and types of common AEs for each biologic were comparable to those of previous trials and other systemic treatments.5,4,3,6,7 Infections